| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
Polidocanol (Nonaethylene glycol monododecyl ether; Nonaoxyethylene monododecyl ether) is a non-ionic surfactant and polyethylene glycol (PEG) detergent used to form initial coalesced O/W emulsion droplets, as well as for protein separation and purification. It is also a local anaesthetic agent and antipruritic agent, and a component of ointments and bath additives. It relieves itching caused by eczema and dry skin.
| ln Vitro |
Research using many long-chain E-PDS from various organisms and a range of nonionic PEG detergents revealed that in vitro treatment with nonaethylene glycol monododecyl ether often produced respiratory quinones formed in vivo. The isoprenoid moiety's equivalent chain length. 2].
|
|---|---|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Peak plasma concentrations are reached within 15 minutes after intravenous administration. Elimination route is not specified. Volume of distribution after intravenous administration is 35-82 L. Systemic clearance is 0.2-0.4 L/min. Metabolism/Metabolites Metabolism has not been determined. Biological Half-Life The half-life is approximately 1.5 hours. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation There is currently no information regarding the clinical use of polidocanol during lactation. While polidocanol is unlikely to have adverse effects on breastfed infants, international guidelines recommend suspending breastfeeding for 2 days after sclerotherapy. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. Protein Binding Plasma protein binding was not measured. |
| References |
|
| Additional Infomation |
Polidocanol is a hydroxyl polyether, a derivative of nonyl glycol, with its terminal hydroxyl group replaced by a dodecyl (lauryl) group. It is a nonionic surfactant, hepatotoxic drug, and sclerosing agent. Its function is similar to that of nonyl glycol. Polidocanol is a sclerosing agent suitable for treating simple spider veins (varicose veins ≤1 mm in diameter) and simple reticular veins (varicose veins 1 to 3 mm in diameter) of the lower extremities. Its trade names are Asclera and Varitena. The structural formula of Polidocanol is C12H25(OCH2CH2)nOH, with an average degree of polymerization (n) of approximately 9 and an average molecular weight of approximately 600. Polidocanol is a lauryl alkyl polyethylene glycol ether with sclerosing effects and potential antitumor activity. Intralesional injection of Polidocanol can induce endothelial cell damage by disrupting calcium signaling and nitric oxide pathways. Following endothelial injury, platelets aggregate at the site of injury and attach to the vein wall, forming a dense network of platelets, cell debris, and fibrin that obstructs the vessel. Inducing endothelial cell damage in melanoma metastases may trigger an antitumor response in untreated peripheral lesions and inhibit the growth of metastases and other skin lesions.
See also: Ethylene oxide (containing monomers)...See more... Drug IndicationsPolydocaine is a sclerosing agent indicated for the treatment of simple spider angiomas and simple reticular veins of the lower extremities. FDA Label Mechanism of ActionAfter administration, polidocaine locally damages the vascular endothelium. Following endothelial injury, platelets aggregate at the site of injury and attach to the vein wall, eventually forming a dense network of platelets, cell debris, and fibrin that obstructs the vessel. Eventually, the vessel is replaced by connective tissue fibrous tissue. PharmacodynamicsPolydocaine has a concentration- and volume-dependent damaging effect on the vascular endothelium. |
| Molecular Formula |
C30H62O10
|
|---|---|
| Molecular Weight |
582.816
|
| Exact Mass |
582.434
|
| CAS # |
3055-99-0
|
| Related CAS # |
9043-30-5
|
| PubChem CID |
656641
|
| Appearance |
White to off-white oil
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
615.9±50.0 °C at 760 mmHg
|
| Melting Point |
33-36ºC
|
| Flash Point |
326.3±30.1 °C
|
| Vapour Pressure |
0.0±4.0 mmHg at 25°C
|
| Index of Refraction |
1.459
|
| LogP |
2.18
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
40
|
| Complexity |
431
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
|
| InChi Key |
ONJQDTZCDSESIW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H62O10/c1-2-3-4-5-6-7-8-9-10-11-13-32-15-17-34-19-21-36-23-25-38-27-29-40-30-28-39-26-24-37-22-20-35-18-16-33-14-12-31/h31H,2-30H2,1H3
|
| Chemical Name |
2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
|
| Synonyms |
Asclera, Aethoxysklerol and Varithena C12E9, Dodecyl nonaethylene glycol ether, Dodecylnonaglycol, Polidocanol, Polyoxyethylene (9) lauryl ether Polidocanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~428.96 mM)
Ethanol : ~100 mg/mL (~171.58 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7158 mL | 8.5790 mL | 17.1580 mL | |
| 5 mM | 0.3432 mL | 1.7158 mL | 3.4316 mL | |
| 10 mM | 0.1716 mL | 0.8579 mL | 1.7158 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
